List view / Grid view
18 February 2016 | By Victoria White
The treatment - an antibody that blocks the MERS virus - was produced by cows that had been genetically modified to mimic certain aspects of the human immune system...
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
17 February 2016 | By Victoria White
Cryptococcus neoformans is a fungus that causes fatal infections in humans with a weakened immune system...
17 February 2016 | By Victoria White
In preclinical studies, Inovio's Zika DNA vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood...
17 February 2016 | By Victoria White
The small peptide has been shown to be an effective at shuttling functional proteins into the spinal cord after a muscle injection...
17 February 2016 | By Victoria White
Scientists have discovered the dual role of IL-36 in both promoting intestinal inflammation and resolving or healing that inflammation in IBD...
16 February 2016 | By Victoria White
A GlobalData analyst says that while a Zika virus vaccine could be an effective measure in the long term, it remains several years away...
16 February 2016 | By Victoria White
Akarna has said it will use the funds to accelerate the development of its lead FXR agonist drug candidate...
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
16 February 2016 | By Victoria White
As part of the I-O RPM programme, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early phase clinical studies...
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
16 February 2016 | By Victoria White
AbbVie has been announced as the latest Dementia Consortium partner, joining MRC Technology, Alzheimer’s Research UK, Astex, Eisai and Lilly...
15 February 2016 | By Victoria White
Researchers say drug discovery processes are becoming unsustainably expensive despite huge technological advances because the wrong methods are being used…
15 February 2016 | By Victoria White
Eisai and Charles River have signed a collaboration agreement which will see Charles River scientists work at Eisai’s research and development facilities in Hatfield...
15 February 2016 | By Victoria White
In addition to establishing the potential for CMV-based vaccines against Ebola virus, these results are exciting from the potential insight they give into the mechanism of protection...
